Buy SB-649-915 (5-HT1A) Cas 420785-70-2

SB-649,915 is a serotonin reuptake inhibitor and 5-HT_1A and 5-HT_1B receptor antagonist which is being investigated for its antidepressant effects.^[1] Relative to the selective serotonin reuptake inhibitors (SSRIs), SB-649,915 has a faster onset of action and may also have greater clinical efficacy as well.^[1] This can be attributed to blockade of 5-HT_1A and 5-HT_1B autoreceptors which inhibit serotonin release.^[1]

5-HT1A antagonist 2 (example 1) is a 5-HT1A antagonist that may be used to study depression or attention deficit hyperactivity disorder (ADHD).

Biological Activity I Assay Protocols (From Reference)

References	[1]. Joachim Nozulak. Silylated heterocyclic compounds. WO2001036428A1.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula	C18H29NOSI
Molecular Weight	303.51
CAS #	340804-57-1
Appearance	Typically exists as solids at room temperature
HS Tariff Code	2934.99.9001
Storage	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)	May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)	Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2:* DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5:* 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.)

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

Oral Formulations

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.2948 mL	16.4739 mL	32.9478 mL
	5 mM	0.6590 mL	3.2948 mL	6.5896 mL
	10 mM	0.3295 mL	1.6474 mL	3.2948 mL

Buy SB-649-915 (5-HT1A) Cas 420785-70-2

MedKoo Cat#: 532675 | Name: SB 649915

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SB 649915 is a serotonin reuptake inhibitor and 5-HT1A and 5-HT1B receptor antagonist which is being investigated for its antidepressant effects. Relative to the selective serotonin reuptake inhibitors (SSRIs), SB-649,915 has a faster onset of action and may also have greater clinical efficacy.

Chemical Structure

SB-649915

CAS No.: 420785-70-2

Cat. No.: VC0542636

Molecular Formula: C26H29N3O3

Molecular Weight: 431.5 g/mol

Purity: >98% (or refer to the Certificate of Analysis)

* For research use only. Not for human or veterinary use.

Specification

CAS No.	420785-70-2
Molecular Formula	C26H29N3O3
Molecular Weight	431.5 g/mol
IUPAC Name	6-[[1-[2-(2-methylquinolin-5-yl)oxyethyl]piperidin-4-yl]methyl]-4H-1,4-benzoxazin-3-one
Standard InChI	InChI=1S/C26H29N3O3/c1-18-5-7-21-22(27-18)3-2-4-24(21)31-14-13-29-11-9-19(10-12-29)15-20-6-8-25-23(16-20)28-26(30)17-32-25/h2-8,16,19H,9-15,17H2,1H3,(H,28,30)
Standard InChI Key	PJSUYRBCBFPCQW-UHFFFAOYSA-N
Canonical SMILES	CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCC(CC3)CC4=CC5=C(C=C4)OCC(=O)N5
Appearance	Solid powder

Introduction

Chemical Identity and Structural Characterization

IUPAC Nomenclature and Molecular Formula

The systematic IUPAC name of the compound is 4-methyl-6-[[1-[2-(2-methylquinolin-5-yl)oxyethyl]piperidin-4-yl]methyl]-1,4-benzoxazin-3-one . Its molecular formula is C27H31N3O3, with a molecular weight of 445.6 g/mol . The SMILES notation (CC1=NC2=C(C=C1)C(=CC=C2)OCCN3CCC(CC3)CC4=CC5=C(C=C4)OCC(=O)N5C) provides a linear representation of its structure, highlighting the benzoxazinone core, piperidine ring, and 2-methylquinolin-5-yl substituent .

Structural Features

The molecule comprises three key moieties:

Benzoxazinone core: A bicyclic structure with oxygen and nitrogen atoms at positions 1 and 4, respectively.
Piperidine ring: Connected to the benzoxazinone via a methylene (-CH2-) group.
2-Methylquinolin-5-yl group: Attached to the piperidine through an ethoxy (-OCH2CH2-) linker .

A 3D conformational analysis reveals flexibility in the ethoxy linker and piperidine ring, which may influence receptor binding .

Pharmacological Activity

Serotonin 1b (5-HT1b) Receptor Inhibition

The compound exhibits inhibitory activity against the 5-HT1b receptor, a G-protein-coupled receptor implicated in migraine, depression, and anxiety . Key findings include:

Ki value: 10.0 nM, indicating moderate potency compared to reference compounds like GR-127935 (Ki = 0.14–4.31 nM) and Sumatriptan (Ki = 23.1 nM) .
Selectivity: Structural analogs with propyloxy linkers (e.g., Smolecule’s S005960) show altered potency, suggesting linker length impacts receptor interaction.

Table 1: Comparative 5-HT1b Receptor Binding Data

Compound Name	Molecular Formula	Ki (nM)	Structural Variant
6-[[1-[2-(2-MQ-5-yl)oxyethyl]piperidin-4-yl]methyl]-4H-1,4-benzoxazin-3-one	C27H31N3O3	10.0	Ethoxy linker
6-[[1-[3-(2-MQ-5-yl)oxypropyl]piperidin-4-yl]methyl]-4H-1,4-benzoxazin-3-one	C27H31N3O3	N/A	Propoxy linker
GR-127935	C19H21FN4O2	0.14	Reference antagonist

Mechanism of Action

The 2-methylquinoline moiety likely engages in π-π stacking with aromatic residues in the 5-HT1b receptor’s binding pocket, while the piperidine ring may stabilize interactions via hydrophobic contacts . The ethoxy linker’s flexibility could permit optimal orientation of the quinoline group.

Synthesis and Derivatives

Synthetic Routes

While explicit synthetic protocols are scarce, retrosynthetic analysis suggests:

Benzoxazinone formation: Condensation of 2-aminophenol derivatives with keto esters.
Piperidine substitution: Alkylation of piperidine with 2-(2-methylquinolin-5-yloxy)ethyl bromide.
Coupling: Mitsunobu or nucleophilic substitution reactions to link the benzoxazinone and piperidine moieties .

Structural Analogs

Propoxy variant: Replacing the ethoxy linker with a propoxy group (Smolecule’s S005960) alters pharmacokinetics but retains the molecular formula.
Quinazoline derivatives: Patented 2,4-diaminoquinazolines (e.g., US7985755B2) share structural motifs but target spinal muscular atrophy .

SB-649915

Catalog No.: A29395

5-HT1A/1B Autoreceptor Antagonist

SB-649915 is a potent antagonist of the 5-HT1A and 5-HT1B autoreceptors, demonstrating pKi values of 8.6 and 8.0, respectively. This compound also acts as a serotonin reuptake inhibitor in native tissue systems, making it valuable for investigating the mechanisms underlying antidepressant therapies. Its ability to modulate serotonergic signaling supports its role in research related to mood disorders and other neuropsychiatric conditions.

Research Implications and Future Directions

Challenges and Limitations

Potency gap: Higher Ki than GR-127935 may limit clinical utility.
Synthetic complexity: Multi-step synthesis complicates large-scale production .

Future Studies

Structure-activity relationships (SAR): Optimizing linker length and substituents.
In vivo efficacy: Testing in animal models of migraine or depression.
Toxicology: Assessing off-target effects and metabolic stability.

SB 649915

CAS#420785-70-2

Theoretical Analysis

MedKoo Cat#: 532675

Name: SB 649915

CAS#: 420785-70-2

Chemical Formula: C26H29N3O3

Exact Mass: 431.2209

Molecular Weight: 431.54

Elemental Analysis: C, 72.37; H, 6.77; N, 9.74; O, 11.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Related CAS #

No Data

Synonym

SB 649915; SB-649915; SB649915.

IUPAC/Chemical Name

6-[[1-[2-(2-methylquinolin-5-yl)oxyethyl]piperidin-4-yl]methyl]-4H-1,4-benzoxazin-3-one

InChi Key

PJSUYRBCBFPCQW-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H29N3O3/c1-18-5-7-21-22(27-18)3-2-4-24(21)31-14-13-29-11-9-19(10-12-29)15-20-6-8-25-23(16-20)28-26(30)17-32-25/h2-8,16,19H,9-15,17H2,1H3,(H,28,30)

SMILES Code

O=C1COC2=CC=C(CC3CCN(CCOC4=C5C=CC(C)=NC5=CC=C4)CC3)C=C2N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 – 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

View History

Delucemine Hydrochloride

MedKoo CAT#: 528314

CAS#: 186495-99-8 (HCl)

Reviews

There are no reviews yet.

Be the first to review “Buy SB-649-915 (5-HT1A) Cas 420785-70-2”

Buy SB-649-915 (5-HT1A) Cas 420785-70-2

Buy SB-649-915 (5-HT1A) Cas 420785-70-2

Buy SB-649-915 (5-HT1A) Cas 420785-70-2

Description:

Chemical Structure

SB-649915

Specification

Introduction

Chemical Identity and Structural Characterization

IUPAC Nomenclature and Molecular Formula

Structural Features

Pharmacological Activity

Serotonin 1b (5-HT1b) Receptor Inhibition

Table 1: Comparative 5-HT1b Receptor Binding Data

Mechanism of Action

Synthesis and Derivatives

Synthetic Routes

Structural Analogs

SB-649915

Research Implications and Future Directions

Challenges and Limitations

Future Studies

Theoretical Analysis

Price and Availability

View History

See also